Supplementary Table 5. Sustained Pain Relief and Sustained Pain Freedom (mITT population): ACHIEVE I and ACHIEVE II

	ACHIEVE I			ACHIEVE II		
Statistics	**Placebo (N=456)**	**Ubrogepant 50 mg (N=423)**	**Ubrogepant 100 mg (N=448)**	**Placebo (N=456)**	**Ubrogepant 25 mg (N=435)**	**Ubrogepant 50 mg (N=464)**
Sustained Pain Relief 2-24 hours						
n/N1 (%)	93/447 (20.8)	150/413 (36.3)	165/434 (38.0)	93/443 (21.0)	138/424 (32.5)	165/449 (36.7)
vs. Placebo						
Odds Ratio (95% CI)		2.25 (1.65, 3.07)	2.39 (1.77, 3.24)		1.82 (1.33, 2.48)	2.16 (1.59, 2.92)
P-value		<.0001	<.0001		0.0002	<.0001
Adjusted p-value		0.0023	0.0023		0.0711	0.0129
Sustained Pain Freedom 2-24 hours						
n/N1 (%)	39/452 (8.6)	53/418 (12.7)	6/418 (15.4)	37/451 (8.2)	55/432 (12.7)	66/457 (14.4)
vs. Placebo						
Odds Ratio (95% CI)		1.57 (1.01, 2.44)	1.95 (1.28, 2.97)		1.62 (1.04, 2.53)	1.85 (1.20, 2.83)
P-value		0.0436	0.0018		0.0317	0.0051
Adjusted p-value		0.0577	0.0037		0.0711	0.0129

N1 = Number of patients with determinable sustained pain relief from 2 to 24 hours after initial dose in the modified intent-to-treat population.

Pain Relief = Reduction of a moderate/severe migraine headache to a mild headache or to no headache.

Sustained Pain Relief = Pain relief at 2 hours with no administration of either rescue medication or optional second dose of trial treatment, and with no occurrence thereafter of a moderate or severe headache during the relevant number of hours after dosing with trial treatment.

Pain Freedom = Reduction in headache severity from moderate/severe at baseline to no pain.

Sustained Pain Freedom = Pain freedom at 2 hours with no administration of either rescue medication or optional second dose of trial treatment, and with no occurrence thereafter of a mild, moderate, or severe headache during the relevant number of hours after dosing with trial treatment.

Determinable cases = Participants for whom sustained pain relief from 2 to 24 hours status can be determined based on observed headache severity at scheduled time points, use of rescue medication or optional second dose between 2 and 24 hours, and the answer to the headache recurrence question at 24 or 48 hours.

Odds Ratio (95% CI) and p-value are based on logistic regression with treatment group, historical triptan response, use of medication for migraine prevention, and baseline headache severity as explanatory variables.

Inferences are based on adjusted p-values that account for multiple comparisons.

Percentages calculated as 100 x (n/N1).